Shinpoong Pharmaceutical, which lost market confidence following clinical trial failures after boosting its stock price by promising to develop the malaria drug 'Pyramax' as a COVID-19 treatment, is aiming for a comeback by expanding its malaria business. This move comes as the company partners with the German pharmaceutical firm Merck to develop a new combination therapy utilizing Pyramax. The strategy is to seek new growth opportunities, given…
Shinpoong Pharmaceutical, which lost market confidence following clinical trial failures after boosting its stock price by promising to develop the malaria drug 'Pyramax' as a COVID-19 treatment, is aiming for a comeback by expanding its malaria business. This move comes as the company partners with the German pharmaceutical firm Merck to develop a new combination therapy utilizing Pyramax. The strategy is to seek new growth opportunities, given…